Nasus Pharma Ltd

Análisis de la acción Nasus Pharma Ltd (NSRX)

$3.825

-0.243 (-6.34%)Al cierre

Loading chart…
High
3.930
Open
3.850
VWAP
3.73
Vol
15.67K
Mkt Cap
Low
3.430
Amount
58.44K
EV/EBITDA, TTM
0.00

Nasus Pharma Ltd. is an Israel-based pharmaceutical company. The Company develops and manufactures pharmaceutical products and intranasal powder-based drug delivery systems. Its proprietary microsphere technology is designed to enable non-invasive intranasal administration of medications for emergency and acute-care applications, including the treatment of anaphylaxis and opioid overdose. The Company's formulations are designed to support rapid drug absorption and administration without the use of injections. Nasus Pharma Ltd. focuses on the development of drug delivery solutions intended for use by healthcare professionals, caregivers, first responders, and other non-professional users. The Company's products aim to improve the accessibility and administration of critical medications in emergency situations.

AI analysis of Nasus Pharma Ltd (NSRX)

buy

Nasus Pharma Ltd is a good buy right now due to its recent price increase of 35.31% over the last 20 days and a current RSI of 78.7, indicating strong momentum. The company has successfully raised $15 million to fund clinical trials, which enhances its financial stability. However, the main risk is the high current liabilities of $4.95 million compared to current assets of only $291,000 in Q2 2025, indicating potential liquidity issues in the short term.

Métricas de valoración

The current forward P/E ratio for Nasus Pharma Ltd (NSRX) is 0.00, compared to its 5-year average forward P/E of -6.16.

Forward P/E

Overvalued
5Y Average P/E
-6.16
Current P/E
0.00
Sobrevalorada
-2.22
Infravalorada
-10.10

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Forward P/S

Fair
5Y Average P/S
0.16
Current P/S
0.00
Sobrevalorada
1.27
Infravalorada
-0.94

Whales holding NSRX

C

Cable Car Capital LLC

+ HoldingNSRX

+0.97%

3M Return

Cronología de eventos

2026-07-28 (ET)

08:01:00

Nasus Pharma Appoints Brendan O'Grady as CEO

2026-03-25 (ET)

09:30:00

Nasus Pharma Advances NS002 Clinical Study

2026-03-16 (ET)

07:40:00

Nasus Pharma NS002 Clinical Trial Results Significantly Outperform EpiPen

2026-03-02 (ET)

17:40:00

Nasus Pharma Files to Sell 5.39M Ordinary Shares

2026-02-23 (ET)

10:30:00

Nasus Pharma Ltd Trading Halted

Noticias

NSRX FAQ — answered by Alphio AI

Nasus Pharma Ltd. is an Israel-based pharmaceutical company. The Company develops and manufactures pharmaceutical products and intranasal powder-based drug delivery systems. Its proprietary microsphere technology is designed to enable non-invasive intranasal administration of medications for emergency and acute-care applications, including the treatment of anaphylaxis and opioid overdose. The Company's formulations are designed to support rapid drug absorption and administration without the use of injections. Nasus Pharma Ltd. focuses on the development of drug delivery solutions intended for use by healthcare professionals, caregivers, first responders, and other non-professional users. The Company's products aim to improve the accessibility and administration of critical medications in emergency situations. It operates in the Healthcare sector.

Nasus Pharma Ltd is a good buy right now due to its recent price increase of 35.31% over the last 20 days and a current RSI of 78.7, indicating strong momentum. The company has successfully raised $15 million to fund clinical trials, which enhances its financial stability. However, the main risk is the high current liabilities of $4.95 million compared to current assets of only $291,000 in Q2 2025, indicating potential liquidity issues in the short term.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis